相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
Pamela N. Munster et al.
CLINICAL CANCER RESEARCH (2022)
Ovarian Cancer, Version 2.2020
Deborah K. Armstrong et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Prognostic Significance of Glucocorticoid Receptor Expression in Cancer: A Systematic Review and Meta-Analysis
Noor Bakour et al.
CANCERS (2021)
Adrenal tumors provide insight into the role of cortisol in NK cell activity
Andrew E. Greenstein et al.
ENDOCRINE-RELATED CANCER (2021)
Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells
Andrew E. Greenstein et al.
Oncotarget (2021)
Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 24, pg 24, 2013)
J. A. Ledermann et al.
ANNALS OF ONCOLOGY (2018)
High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer
Jennifer Taylor Veneris et al.
GYNECOLOGIC ONCOLOGY (2017)
Identification of the Clinical Candidate (R)-(1-(4-Fluoropheny1)-6-((1methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist
Hazel J. Hunt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay
Thaddeus S. Block et al.
CANCER MANAGEMENT AND RESEARCH (2017)
Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy
Yasunori Hashiguchi et al.
ANTI-CANCER DRUGS (2015)
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma
Erica M. Stringer-Reasor et al.
GYNECOLOGIC ONCOLOGY (2015)
Platinum resistant ovarian cancer: What is it, who to treat and how to measure benefit?
Alison Davis et al.
GYNECOLOGIC ONCOLOGY (2014)
The PROMIS Physical Function item bank was calibrated to a standardized metric and shown to improve measurement efficiency
Matthias Rose et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2014)
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential
Daniela Luvero et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. A. Ledermann et al.
ANNALS OF ONCOLOGY (2013)
Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer
Maxwell N. Skor et al.
CLINICAL CANCER RESEARCH (2013)
A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study
Robert L. Coleman et al.
GYNECOLOGIC ONCOLOGY (2011)
A new index of priority symptoms in advanced ovarian cancer
Sally E. Jensen et al.
GYNECOLOGIC ONCOLOGY (2011)
Administration of Glucocorticoids to Ovarian Cancer Patients Is Associated with Expression of the Anti-apoptotic Genes SGK1 and MKP1/DUSP1 in Ovarian Tissues
Amal Melhem et al.
CLINICAL CANCER RESEARCH (2009)
Evaluation of a preliminary physical function item bank supported the expected advantages of the Patient-Reported Outcomes Measurement Information System (PROMIS)
M. Rose et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2008)
Tat-Induced FOXO3a Is a Key Mediator of Apoptosis in HIV-1-Infected Human CD4+ T Lymphocytes
Alicja Dabrowska et al.
JOURNAL OF IMMUNOLOGY (2008)
The Patient-Reported Outcomes Measurement Information System (PROMIS) Progress of an NIH roadmap cooperative group during its first two years
David Cella et al.
MEDICAL CARE (2007)
Albumin-bound paclitaxel: a next-generation taxane
William J. Gradishar
EXPERT OPINION ON PHARMACOTHERAPY (2006)
分享论文
